创新药板块再迎多重利好!创新药ETF天弘(517380)连续两日“吸金”，生物医药ETF(159859)盘中净申购超2800万

格隆汇2025-06-27

今日创新药概念股震荡走强，迈威生物20cm涨停，华人健康、锦波生物涨超10%，生物医药ETF(159859)涨0.28%，创新药ETF天弘(517380)小幅下跌0.6%。消息面上： ①国家医疗保障局近日印发《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调整方案。 ②由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2546764507?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-27 10:47","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2546764507","market":"sh","top_or_hot":-1,"title":"创新药板块再迎多重利好!创新药ETF天弘(517380)连续两日“吸金”，生物医药ETF(159859)盘中净申购超2800万","media":"格隆汇","content":"<div>\n<p>今日创新药概念股震荡走强，迈威生物20cm涨停，华人健康、锦波生物涨超10%，生物医药ETF(159859)涨0.28%，创新药ETF天弘(517380)小幅下跌0.6%。\n消息面上：\n①国家医疗保障局近日印发《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调整方案。\n②由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创新药板块再迎多重利好!创新药ETF天弘(517380)连续两日“吸金”，生物医药ETF(159859)盘中净申购超2800万</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创新药板块再迎多重利好!创新药ETF天弘(517380)连续两日“吸金”，生物医药ETF(159859)盘中净申购超2800万\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-27 10:47 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今日创新药概念股震荡走强，迈威生物20cm涨停，华人健康、锦波生物涨超10%，生物医药ETF(159859)涨0.28%，创新药ETF天弘(517380)小幅下跌0.6%。\n消息面上：\n①国家医疗保障局近日印发《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调整方案。\n②由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2546764507","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546764507","pubTimestamp":1750992431,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"今日创新药概念股震荡走强，迈威生物20cm涨停，华人健康、锦波生物涨超10%，生物医药ETF(159859)涨0.28%，创新药ETF天弘(517380)小幅下跌0.6%。\n消息面上：\n①国家医疗保障","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159217":"港创新药","159646":"疫苗","159859":"生物药30","159891":"医疗","159938":"医药","159982":"中证500","159992":"创新药","161726":"生物医药","301408":"华人健康","399300":"沪深300","399441":"生物医药","512290":"生物医药ETF国泰","515120":"创新药ETF广发","688062":"迈威生物-U","CXO.AU":"CORE LITHIUM LTD","BK4614":"Manus概念股","BK7504":"锂钴概念","BK4588":"碎股","BK4550":"红杉资本持仓","BK1589":"北水核心资产","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1141":"生命科学工具和服务","FDN":"First Trust Dow Jones Internet I","BK0239":"医药制造","BK1576":"医药外包概念","03347":"泰格医药","BK0209":"零售","BK1161":"生物科技","GLP":"Global Partners Lp","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01801":"信达生物","07226":"南方两倍做多恒科","BK4144":"石油与天然气的储存和运输","YANG":"三倍做空富时中国ETF-Direxion","BK4590":"PTP","BK1515":"抗疫概念","06978":"永泰生物-B","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","HSCEI":"国企指数","CXO":"康休","BK7095":"多种金属与采矿","BK1583":"高瓴概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","HSTECH":"恒生科技指数","09939":"开拓药业-B"},"translate_title":"The innovative drug sector welcomes multiple benefits again! Innovative drug ETF Tianhong (517380) has \"attracted gold\" for two consecutive days, and biomedical ETF (159859) has a net intraday subscription of more than 28 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159217":1,"159646":1,"159859":1,"159891":1,"159938":1,"159982":1,"159992":1,"161726":1,"301408":1,"399300":1,"399441":1,"512290":1,"515120":1,"688062":1,"01801":1,"CXO":1,"YANG":1,"FDN":1,"07226":1,"09939":1,"CXO.AU":1,"03347":1,"GLP":1,"HSTECH":1,"06978":1,"HSCEI":1},"content_text":"今日创新药概念股震荡走强，迈威生物20cm涨停，华人健康、锦波生物涨超10%，生物医药ETF(159859)涨0.28%，创新药ETF天弘(517380)小幅下跌0.6%。\n消息面上：\n①国家医疗保障局近日印发《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调整方案。\n②由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周获批。\n③6月16日，《关于优化创新药临床试验审评审批有关事项的公告（征求意见稿）》意见。，审批效率提升将加速优质管线价值释放，提振市场对创新药板块的风险偏好\n创新药震荡期间，资金坚定借道ETF布局，创新药ETF天弘(517380)连续两日吸金，近10个交易日有8日获资金净申购，合计净流入5673万元。\n全市场独家品种·创新药ETF天弘(517380)及联接基金(A类014564， C类014565)是全市场唯一跟踪恒生沪深港创新药精选50指数的ETF，实现了A股+港股、创新药+CXO全面覆盖，该产品年内涨幅24%。\n生物医药ETF(159859)盘中获资金净申购2880万份，昨日净流入7646万元，稳居同标的第一。\n生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546764507","isCrawlerRequest":true}